Analysts Offer Insights on Healthcare Companies: Lineage Cell Therapeutics (NYSE MKT: LCTX), Intercept Pharma (NASDAQ: ICPT) and BioDelivery (NASDAQ: BDSI)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lineage Cell Therapeutics (LCTXResearch Report), Intercept Pharma (ICPTResearch Report) and BioDelivery (BDSIResearch Report) with bullish sentiments.

Lineage Cell Therapeutics (LCTX)

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Lineage Cell Therapeutics today and set a price target of $4.00. The company’s shares closed last Tuesday at $0.90.

According to TipRanks.com, Nakae is a 4-star analyst with an average return of 9.3% and a 49.1% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Emergent Biosolutions, and Arcturus Therapeutics.

Currently, the analyst consensus on Lineage Cell Therapeutics is a Strong Buy with an average price target of $3.67, which is a 298.9% upside from current levels. In a report issued on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.

See today’s analyst top recommended stocks >>

Intercept Pharma (ICPT)

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Intercept Pharma yesterday and set a price target of $165.00. The company’s shares closed last Tuesday at $92.79.

According to TipRanks.com, Nash is a 4-star analyst with an average return of 7.5% and a 43.1% success rate. Nash covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Galmed Pharmaceuticals, and Akero Therapeutics.

Intercept Pharma has an analyst consensus of Strong Buy, with a price target consensus of $148.69, representing a 69.4% upside. In a report issued on May 1, Wedbush also maintained a Buy rating on the stock with a $257.00 price target.

BioDelivery (BDSI)

In a report released yesterday, Tim Chiang from Northland Securities maintained a Buy rating on BioDelivery, with a price target of $9.00. The company’s shares closed last Tuesday at $4.80.

Chiang has an average return of 3.2% when recommending BioDelivery.

According to TipRanks.com, Chiang is ranked #3923 out of 6562 analysts.

BioDelivery has an analyst consensus of Strong Buy, with a price target consensus of $7.33, a 44.3% upside from current levels. In a report issued on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.